Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
NCT ID: NCT01126034
Last Updated: 2015-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
85 participants
INTERVENTIONAL
2007-03-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1\) an intervention targeted at the prescribing physician would increase the rate of a metoclopramide discontinuation among patients prescribed the medication for questionable or unclear indications; and 2) the discontinuation would be durable.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intervention
Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:
1. The name and medical record # of the patients involved
2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy
3. A reminder of the adverse effect of long-term metoclopramide therapy
4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients
5. A request that the physician document the discontinuation trial in the electronic medical record
intervention letter
Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:
1. The name and medical record # of the patients involved
2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy
3. A reminder of the adverse effect of long-term metoclopramide therapy
4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients
5. A request that the physician document the discontinuation trial in the electronic medical record
non-intervention
No intervention letters were sent to subjects in this arm
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intervention letter
Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:
1. The name and medical record # of the patients involved
2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy
3. A reminder of the adverse effect of long-term metoclopramide therapy
4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients
5. A request that the physician document the discontinuation trial in the electronic medical record
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Physicians how were investigators on this study
* Physicians serving on the the University of Pennsylvania Drug Use and Effects Committee or Information Technology Oversight Board
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yu-Xiao Yang, MD, MSCE
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pennsylvania Center for Clinical Epidemiology and Biostatistics
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UPenn - 802142
Identifier Type: -
Identifier Source: org_study_id